References
- Adam D. Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2002; 50 (Topic T1): 1–5.
- Moreno S, García-Leoni ME, Cercenado E, Diaz MD, Bernaldo de Quirós JC, Bouza E. Infections caused by erythromycin- resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 1995; 20: 1195–1200.
- Kelly MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008–1011.
- Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556–564.
- Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747–750
- Bastida T, Pérez-Vázquez M, Campos J, et al. Levofloxacin treatment failure in Haemophilus influenzae pneumonia. Emerg Infect Dis 2003; 9: 1475–1478.
- Ackermann G, Rodloff AC. Drugs of the 21st century: telithromycin (HMR 3647) – the first ketolide. J Antimicrob Chemother 2003; 51: 497–511.
- Hansen LH, Mauvais P, Douthwaite S. The macrolideketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Molecular Microbiology 1999; 31: 623–631.
- Bonnefoy A, Girard AM, Agouridas C, Chantot JF. Ketolides lack inducibility properties of MLSB resistance phenotype. J Antimicrob Chemother 1997; 40: 85–90.
- Giovanetti E, Montanari MP, Marchetti F, Varaldo PE. In vitro activity of ketolides telithromycin and HMR 3004 against Italian isolates if Streptococcus pneumoniae and Streptococcus pyogenes with different erythromycin susceptibility. J Antimicrob Chemother 2000; 46: 905–908.
- Schmitz F-J, Petridou J, Milatovic D, Verhoef J, Fluit AC, Schwarz S. In vitro activity of new ketolides against macrolide-susceptible and –resistant Staphylococcus aureus isolates with defined resistance gene status. J Antimicrob Chemother 2002; 49: 573–584.
- Aventis Pharma. Ketek (telithromycin) Briefing Document for the FDA Anti-Infective Drug Products Advisory Committee Meeting, January 2003 (http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1 _01_Aventis-KETEK.pdf).
- Barman Balfour JA, Figgitt DP. Telithromycin. Drugs 2001; 61: 815–829.
- Leclercq R. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. J Antimicrob Chemother 2001; 48 (Topic T1): 9–23.